Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Gross Profit Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual gross profit in 2023 was -223 Million USD , up 3.06% from previous year.
Arcus Biosciences, Inc.'s latest quarterly gross profit in 2024 Q2 was 37 Million USD , down -73.94% from previous quarter.
Arcus Biosciences, Inc. reported a annual gross profit of 98 Million USD in annual gross profit 2022, down -73.92% from previous year.
Arcus Biosciences, Inc. reported a annual gross profit of 375.82 Million USD in annual gross profit 2021, up 561.23% from previous year.
Arcus Biosciences, Inc. reported a quarterly gross profit of 142 Million USD for 2024 Q1, up 446.15% from previous quarter.
Arcus Biosciences, Inc. reported a quarterly gross profit of 25 Million USD for 2023 Q2, up 19.05% from previous quarter.

Annual Gross Profit Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Gross Profit of Arcus Biosciences, Inc. (2023 - 2016)

Year	Gross Profit	Gross Profit Growth
2023	-223 Million USD	3.06%
2022	98 Million USD	-73.92%
2021	375.82 Million USD	561.23%
2020	-81.48 Million USD	-28.36%
2019	-63.48 Million USD	-53.73%
2018	-41.29 Million USD	-3343.95%
2017	-1.19 Million USD	8.75%
2016	-1.31 Million USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	37 Million USD	-73.94%
2024 Q1	142 Million USD	446.15%
2023 Q2	25 Million USD	19.05%
2023 FY	101 Million USD	3.06%
2023 Q1	21 Million USD	780.93%
2023 Q3	29 Million USD	16.0%
2023 Q4	26 Million USD	-10.34%
2022 Q2	23.23 Million USD	59.42%
2022 Q4	-3.08 Million USD	-110.29%
2022 FY	98 Million USD	-73.92%
2022 Q1	14.57 Million USD	-95.86%
2022 Q3	29.97 Million USD	29.02%
2021 Q1	-56.92 Million USD	-45.13%
2021 FY	375.82 Million USD	561.23%
2021 Q2	-59.31 Million USD	-4.19%
2021 Q4	352.02 Million USD	669.69%
2021 Q3	-61.79 Million USD	-4.19%
2020 FY	-81.48 Million USD	-28.36%
2020 Q1	-21.39 Million USD	-95.61%
2020 Q2	-33.94 Million USD	-58.67%
2020 Q3	12.72 Million USD	137.5%
2020 Q4	-39.22 Million USD	-408.15%
2019 Q4	-10.93 Million USD	29.4%
2019 Q3	-15.49 Million USD	33.37%
2019 Q2	-23.24 Million USD	-68.42%
2019 Q1	-13.8 Million USD	-39.8%
2019 FY	-63.48 Million USD	-53.73%
2018 Q3	-8.56 Million USD	31.18%
2018 FY	-41.29 Million USD	-3343.95%
2018 Q2	-12.44 Million USD	-19.68%
2018 Q1	-10.4 Million USD	4.53%
2018 Q4	-9.87 Million USD	-15.24%
2017 Q1	-5.8 Million USD	0.0%
2017 FY	-1.19 Million USD	8.75%
2017 Q4	-10.89 Million USD	48.78%
2017 Q3	-21.27 Million USD	-171.53%
2017 Q2	-7.83 Million USD	-34.98%
2016 FY	-1.31 Million USD	0.0%

Peer Gross Profit Comparison of Arcus Biosciences, Inc.

Name	Gross Profit	Gross Profit Difference
ADC Therapeutics SA	67.02 Million USD	432.692%
Alto Neuroscience, Inc.	-373 Thousand USD	-59685.523%
Annovis Bio, Inc.	- USD	Infinity%
Biohaven Pharmaceutical Holding Company Ltd.	-3.36 Million USD	-6519.175%
Ginkgo Bioworks Holdings, Inc.	197.45 Million USD	212.94%
Nuvation Bio Inc.	-222 Thousand USD	-100350.45%
Nuvation Bio Inc.	-222 Thousand USD	-100350.45%
Theriva Biologics, Inc.	-135 Thousand USD	-165085.185%
Zymeworks Inc.	-66.97 Million USD	-232.95%